Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FEZF1-AS1 siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
FEZF1-AS1 siRNA is a small interfering RNA designed to silence the long non-coding RNA (lncRNA) FEZF1-AS1. In the context of non-small cell lung cancer (NSCLC), FEZF1-AS1 is frequently overexpressed and contributes to cisplatin resistance by acting as a competitive endogenous RNA (ceRNA) that sponges miR-32-5p. This sequestration prevents miR-32-5p from inhibiting its target, Glutaminase (GLS), a key enzyme in glutamine metabolism. By delivering FEZF1-AS1 siRNA, the levels of the lncRNA are reduced, which restores miR-32-5p activity, downregulates GLS expression, and consequently sensitizes cancer cells to cisplatin-based chemotherapy. Experimental studies in NSCLC cell lines and xenograft mouse models have demonstrated that blocking FEZF1-AS1 can effectively overcome chemoresistance.
- Other names
- si-FEZF1-AS1si-FEZF-1-AS1si-FEZF 1-AS1FEZF1-AS1 small interfering RNAFEZF-1-AS1 small interfering RNAFEZF 1-AS1 small interfering RNA
02
Targets
FEZF1-AS1 (FEZF1 antisense RNA 1)
Beyond the preview
Go deeper on FEZF1-AS1 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FEZF1-AS1 siRNA.